DS
NGM

David Shaw’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

David Shaw’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-308,104
Closed -$265K – 4852
2023
Q4 		$265K Sell
308,104
-14,368
-4% -$12.6K ﹤0.01% 3790
2023
Q3 		$345K Sell
322,472
-32,418
-9% -$67.1K ﹤0.01% 3563
2023
Q2 		$919K Buy
354,890
+77,816
+28% +$278K ﹤0.01% 3147
2023
Q1 		$1.13M Buy
277,074
+154,118
+125% +$712K ﹤0.01% 3083
2022
Q4 		$617K Sell
122,956
-16,301
-12% -$102K ﹤0.01% 3737
2022
Q3 		$1.82M Sell
139,257
-21,608
-13% -$327K ﹤0.01% 3095
2022
Q2 		$2.06M Buy
160,865
+97,468
+154% +$1.35M ﹤0.01% 3041
2022
Q1 		$967K Buy
63,397
+3,366
+6% +$52.5K ﹤0.01% 3946
2021
Q4 		$1.06M Buy
60,031
+14,953
+33% +$287K ﹤0.01% 3883
2021
Q3 		$948K Sell
45,078
-60
-0.1% -$1.32K ﹤0.01% 3642
2021
Q2 		$890K Buy
45,138
+34,950
+343% +$818K ﹤0.01% 3636
2021
Q1 		$296K Buy
+10,188
New +$285K ﹤0.01% 3715

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

David Shaw's NGM Position: Q1 2024 in Review

David Shaw sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 308,104 shares — an estimated $265K sold.

David Shaw first reported a position in NGM in Q1 2021 and held it in 12 quarters. The position peaked at $2.06M in Q2 2022. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • David Shaw reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • David Shaw sold 308,104 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $265K.
  • David Shaw first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
  • David Shaw's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $2.06M in Q2 2022.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.